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Abstract: Receptor identification is an integral part of drug discovery 
and development. By the beginning of the next millennium, the search for 
the natural ligands of the orphan G-protein-coupled receptors will lead to 
the discovery of so many new peptides that it may well double their present 
number. It has recently become evident that all types of chemical messengers, 
hormones and transmitters act through membrane receptors which constitute 
our largest superfamily of proteins, i.e. the G protein-coupled receptors. The 
development of targeted therapies has revolutionized the treatment of various 
chronic diseases. Receptors have well-conserved regions that are recognized 
and activated by hormones and neurotransmitters. These ligands are peptides, 
lipids or biogenic amines, and act as transmitter molecules. Identification of 
orphan receptors include screening, binding and reverse engineering that 
help to find out cysteinyl leukotriene CysLT1 and Cys T2, hepatointestinal 
leukotriene B4, motilin, Ghrelin, Growth hormone-releasing peptide and 
growth hormone secretagogue receptor and many more. Techniques involved 
in screening of receptors include low stringency hybridization followed by 
PCR-derived approaches helps to discover various orphan g protein couple 
recptors (oGPCR). The discovery of the oGPCR represents a hallmark in 
neuroscience research, and the exploitation of its numerous physiological 
and pathophysiological functions is a promising avenue for therapeutic 
applications 
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1. InTRoDuCTIon
1.0 Receptor identification is an integral part of drug discovery and development 
process. Most of receptors are initially marked as orphan receptors, with the 





and physiological activity not known. Most receptors show following gross 
structure
 A/B: Amino terminal (With free amino group) (ligand independent 
Transcription activator)
 C: DNA binding domain
 D: hinge Domain
 E: Ligand binding domain
Stimuli that elicit a response from a receptor vary from neurotransmitters, 
hormones, light, which specifically activate intracellular signaling events 
mediated by various intracellular proteins. Receptors are a necessary interface 
in the plasma membrane for interaction with diverse extracellular mediators 
and thereby initiation of cellular responses. Thus development of many pivotal 
therapeutic agents involves interactive and structural studies on membrane 
receptors. A natural activating ligand being integral for activation and 
response of a receptor, ligand discovery for orphan receptors might give an 
idea to discovering new cellular substances with physiological and therapeutic 
potential. This process of ‘ligand discovery for orphan receptors (ligand not 
defined) is key to drug discovery.
The complete identification process may be done by use of two 
methodologies:
I. Identification of receptors after screening, those bind to a particular 
transmitter/ligand structure.
II. Identification of Ligand that bind to a particular receptor (reverse 
engineering)
Sarau, H.M. et al. (1999) carried out identification, molecular cloning, 
expression, and characterization of a cysteinyl leukotriene receptor. Lynch, K.R. 
et al. (1999) carried out characterization of the human cysteinyl leukotriene 
CysLT1 receptor. Heise, C.E. et al. (2000) carried out characterization of the 
human cysteinyl leukotriene 2 (CysLT2) receptor.
Wang, S. et al. (2000) identified a novel hepatointestinal leukotriene B4 
receptor and determined its cloning and functional characterization. 
Feighner, S.D. et al. (1999) identified receptor for motilin in the human 
gastrointestinal system.
Kojima, M. et al. (1999) confirmed that Ghrelin is a growthhormone-
releasing acylated peptide from stomach. Bowers, C.Y. (1998) confirmed 








Patchett, A.A. et al. (1995), carried out design and biological activities of 
L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue. 
1.1 Techniques for discovery:
Bruce Blumberg and Ronald M. Evans (1998)
I. Those focusing on concept first as above, that of screening receptors 
against a particular transmitter:
These include:
 A. PCR based homology screening approaches.
 B.  Low stringency Hybridisation studies followed by PCR-derived 
approaches
Most of the GPCRs started as orphans. Their discoveries stemmed from the 
concept that GPCRs would belong to a supergene family and thus would 
share sequence similarities. Homology screening techniques, low stringency 
hybridization (Bunzow et al., 1988, 1992) soon followed by PCR-derived 
approaches (Libert et al., 1989), paved the way for the discoveries of new 
GPCRs, thus that, by the end of the 1980s, it became clear that the number of 
GPCRs would be large. This was confirmed, at the turn of the century, with 
the sequence of the genome. Today, one estimates that the number of GPCRs 
is about 800, of which more than half are olfactory GPCRs (Vassilatis et al., 
2003).
II. Those focusing on concept second as above, that of screening transmitters 
against a particular receptor (Reverse engineering): 
These include:
 A. Quantification of intracellular cAMP level changes.
 B.  Quantification of Adenyl cyclase activity (Binding as well as activation 
confirmation).
 C. Changes in intracellular Calcium release.
 D. Phospholipase A2 activity
 E. Phospholipase C activity
The first deorphanized GPCRs, the 5HT-1A and the D2 dopamine receptors, 
were already reported in 1988 (Fargin et al., 1988; Bunzow et al., 1988). 
The strategies used were the same, that is, membranes of eukaryotic cells, 
with orphan GPCR expressed by DNA transfection, used as targets to 
determine the binding of potential transmitters. This strategy has come to 






The second successful attempt at discovering novel transmitter through 
orphan GPCRs was done by measuring intracellular calcium release when 
GPCRs wee subjected to peptidic extracts. By this way, two ligand peptides 
were identified named the orexins (Oxs) (Sakurai et al., 1998), and hypocretins 
(Hcrts) (de Lecea et al., 1998) (also identified through an RNA subtraction 
approach). Two more novel ligand peptides, prolactin-releasing peptide, and 
apelin were discovered as the natural ligands of the orphan GPCRs GPR10 and 
APJ, respectively (Hinuma et al., 1998; Tatemoto et al., 1998).
1.2 Transmitter/Ligand classification
Most of the receptors are activated by a plethora of ‘‘transmitters’’ (Civelli 
et al., 2001), or messengers that carry a message to the cell as an endocrine, 
paracrine, or exocrine activity to initiate a particular physiological change. 
Transmitters include nucleotides, amino acid and derivatives, biogenic amines, 
olfactory and gustatory molecules, neuropeptides, chemokines, lipid mediators, 
pheromones, polypeptide hormones, and some other naturally occurring 
chemicals such as calcium ions and protons.
Traditionally, the GPCRs are expected to exhibit specificity for the 
transmitters (Goldstein, 1974). This specificity results from evolutionary 
processes that aim at diversifying the intercellular interactions. A transmitter 
may be the natural ligand of more than one GPCR, but those then share a 
higher degree of homology that groups them into a subfamily. Also a GPCR 
may bind more than one transmitter, but then these transmitters share structural 
similarities and are often part of the same synthesis pathway, as in the case of the 
neuropeptides synthesized from the same precursor (Douglass et al., 1984).
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Detailed analysis of oGPCRs has led to several significant discoveries, 
some of which are presented. Of particular interest is the sheer number of 
recent successful orphan searches driven in part by improvements in assay 
methodology. Since 1988 these include identification of the receptors for:
1 5-HT (Andrew D Howard et al, 2001) adenosine (Lee, Y.K., and Moore, 
D.D. 2008). (Lee, J.M., et al 2011). 
2 Nociceptin/orphanin FQ (Reinscheid, R.K. et al., 1995), (Meunier, J.C. et 
al.,1995) anaphylatoxin C3a Ames, (R.S. et al. 1996) 
3 GHS (Howard, A.D. et al., 1996) 
4 Prolactin-releasing peptide (Hinuma, S. et al., 1998) 
5 Calcitonin generelated peptide or adrenomedullin (Aiyar, N. et al. 1996), 
(McLatchie, L.M. et al.1998) 
6 Hypocretins (orexins) (Sakurai, T. et al. 1998), (de Lecea, L. et al.1998) 
7 Apelin (Tatemoto, K. et al. 1998) 
8 Thyrotropin-releasing hormone (Itadani, H. et al.1998), Cao, J. et al. 
1998) 
9 Cysteinyl leukotrienes (Sarau, H.M. et al. 1999), (Lynch, K.R. et al. 1999), 
(Heise, C.E. et al. 2000), (Wang, S. et al. 2000) 
10 Motilin (Feighner, S.D. et al. 1999) 
11 Melanin-concentrating hormone (Saito, Y. et al. 1999), (Chambers, J. et 
al. 1999), (Shimomura, Y. et al. 1999), (Bachner, D. et al. 1999), (Lembo, 
P.M. et al. 1999) 
12 Urotensin II (Liu, Q. et al. 1999) (Mori, M. et al. 1999) (Ames, R.S. et al. 
1999) (Nothacker, H.P. et al. 1999) 
13 S1P (Okamoto, H. et al. 1999) (An, S. et al. 2000) (Pyne, S. and Pyne, N.J. 
2000) (Lee, M.J. et al. 1998) (Im, D.S. et al. 2000) 
14 Lysophosphatidic acid (Im, D.S. et al. 2000) (Fukushima, N. et al. 
1998) 
15 Leukotriene B4 (Kamohara, M. et al. 2000) (Yokomizo, T. et al. 1997) 
16 Allostatin-like Birgul, N. et al. 1999) (Lenz, C. et al. 2000) 
17 Histamine (Lovenberg, T.W. et al. 1999) 
18 Eskine (Jarmin, D.I. et al. 2000) 
19 UDPglucose (Chambers, J.K. et al. 2000) 
20 Sphingosylphosphorylcholine (Xu, Y. et al. 2000) 
21 Neuromedin U, neuropeptide FF (Hedrick, J.A. et al. 2000) (Elshourbagy, 
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5 Prolactin releasing peptide
6 Apelin
7 PrPP ligands




















Thompson et al., (2012) studied and elucidated the structure of the nociceptin/
orphanin FQ receptor in complex with a peptide mimetic (Thompson et al., 
2012) 
Mogil and Pasternak, (2001) studied the molecular and behavioral 
Pharmacology of the Orphanin FQ/Nociceptin Peptide and Receptor Family. 
This heptadecapeptide binds to the NOP
1








with exceedingly high affinity, but does not interact directly with classical 
opioid receptors. Functionally, the actions of OFQ/N are diverse and 
intriguing. Most work has focused upon pain mechanisms, where OFQ/N 
has potent anti-analgesic actions supraspinally and analgesic actions spinally 
(Mogil and Pasternak, 2001).
Chandrasekaran et al., (2008) studied the role of apelin in cardiovascular 
function and heart failure. Apelin is a novel peptide, widely distributed in a 
number of tissues, mainly restricted to vascular endothelium, and is a ligand for 
APJ receptor similar to the angiotensin II–angiotensin II type 1 receptor pathway. 
It is a peripheral vasodilator, powerful inotrope and may affect central fluid 
homeostasis and is involved in the pathogenesis of heart failure by modulating 
the harmful effects of angiotensin II. Apelin is reduced in patients with heart 
failure and up regulated following favourable left ventricular remodelling. 
Sato et al (2013) confirmed that Apelin is a positive regulator of ACE2 
in failing hearts. Apelin, RAS and ACE2 together form an axis which helps 
increase the contractility of heart and provides a therapeutic target for 
cardiological disorders.
Smith et al., (2001) studied various growth hormone secretagogue receptor 
(GHS-R) family members and its ligands such as L-692,429 and MK-0677. 
Adenosine is a partial agonist of the GHS-R and that motilin is the endogenous 
ligand for GPR38. 
Wurtman RJ (2006) studied relationship between narcolepsy and the 
hypocretins. 
In a narcoleptic patient, “automatic behavior,” refers to daytime sleep 
episode in which conventional functions are done but forgotten once awake. 
Genetic factors alone can not be singled out as a single major cause, as a 
mutation in chromosome 6 controlling the HLA antigen immune complex, 
is seen in narcoleptics as well as nonnarcoleptics. Narcoleptic patients show 
drastic decrease in Cerebrospinal fluid (CSF) hypocretin levels, and a specific 
reduction in hypocretin-containing neurons which may be due to mutation on 
chromosome 12 which disrupts the processing of Hypocretin, whereas HLA 
subtype resulting from the mutation on chromosome 6 may also increase the 
susceptibility of hypocretin-containing brain neurons to immune attack. This 
loss of neurons with Hypocretin causes REM sleep at inappropriate times. 
The hypocretins and orexins are neuropeptides with same precursor 
expressed mainly in lateral hypothalamus neurons. Hypocretins act as ligands for 
two G-protein coupled receptors distributed within the central nervous system in 
Hypocretin neuron fibers in several areas implicated in regulation of the sleep/
wakefulness cycle (De Lecea and Sutcliffe, 2005). Synthetic hypocretin-1 affects 





activity, causes wakefulness, suppressing REM sleep, by integrating homeostatic, 
metabolic and limbic information and providing a coherent output. 
Brighton et al., (2004) elaborated neuromedin U and its receptors: structure, 
function, and physiological roles. Neuromedin U (NmU) a neuropeptide is 
variably distributed, mainly in the GIT and pituitary with two G-protein-
coupled receptors for NmU being recently cloned and the receptors being 
widespread throughout the body but with differential distributions. It shows 
contraction of smooth-muscle (hence the suffix “U”), regulation of BP and 
local blood flow, feeding behavior, stress responses, gastric acid secretion, 
pronociception.
Expression of cortistatin was observed in peptidergic nociceptors of 
the peripheral nociceptive system, and endogenous cortistatin is involved 
in modifying pain sensitization, in inflammatory diseases, by acting both 
peripherally and centrally & modifying tactile allodynia and heat hyperalgesia 
due to arthritis and peripheral tissue inflammation in mice, via mechanisms 
different than antiinflammatory action, involving nociceptive neurons and 
central sensitization, which may be due to impairment of ERK signaling, 
activation of the G protein subunit Gαi, binding of the neuropeptide to 
somatostatin and ghrelin receptors, and decreased production of calcitonin 
gene-related peptide in primary nociceptors (Morell et al., 2013).
1.4 pharmacological Targeting of receptors with Ligands
1.4.1 Retinoic Acid receptors
Discovered as RORα, RORβ, RORγ in liver, skeletal muscles, lungs, thymus 
tissues etc. RORγ is more expressed in immune tissues, thymus, liver, kidneys 
etc. RORα and RORγ play a key role in immune response and generation and 
differentiation of CD4+ T cells into TH1, TH2, TH17 etc. Many ligands have 
been found to configurate with RORα and include Cholesterol, Cholesterol 
Sulphate, Hydroxycholesterol, 0901317, T1317, SR10001 and Ursolic acid 
(Mangelsdorf & Evanst, 1995). The RXR Heterodimers and Orphan Receptors 
Crystallographic studies of RORα suggested that a sterol such as cholesterol 
or cholesterol sulfate may function as a natural ligand of this receptor (Kallen 
et al., 2004). It was also found that hydroxycholesterols were high affinity 
ligands for both RORa and RORg and that some of these such as 7-oxygenated 
sterols functioned as inverse agonists suppressing the constitutive activity of 
both of these receptors (Wang et al., 2010a, 2010b). Huh et al. (2011) also 
identified a small molecule inhibitor of RORg and this compound was the 
well-known cardiac glycoside, digoxin. Ursolic acid has also been recently 








2011). Ursolic acid also delayed the onset and decreased the severity of EAE 
in mice (Xu et al., 2011).
1.4.2 PPARγ receptors and their ligands and Type 2 Diabetes
Type II Diabetes is caused due to development of insulin resistance on cell 
surface, sometimes by adipose tissue increase and obesity, and by the adipokines 
secreted by adipose tissues including TNFα, IL-1, resistin, which prevent 
proper movement of plasma glucose and its redistribution. is one of the prime 
reasons as which decrease insulin sensitivity. Adiponectin and compounds 
like Thiazolidine diones and SR 1664 act in a similar fashion as Adiponectin 
(Forman et al. 1995c; Kliewer et al. 1995; Chawla et al. 1994; Tontonoz et al. 
1994; Ricote et al. 1998; Jiang et al. 1998) increase the insulin sensitization 
(Kershaw & Flier, 2004) (Hotamisligil et al., 1993; Lagathu et al., 2006; 
Steppan et al., 2001). Conversely, adipose tissues from lean individuals secrete 
higher levels of adiponectin, a circulating protein that has insulin-sensitizing 
effects on liver and other tissues (Berg et al., 2001; Hu et al., 1996; Yamauchi 
et al., 2006). 
1.4.3 Liver receptor homolog-1 (LRh-1) and associated ligands
Many ligands have been screened against this receptor expressed in the intestine 
liver, pancreas and ovary and playing important role in embryonic development, 
and the prominent transmitters discovered include Dilaurylphosphatidyl 
Choline (DLPC) and Diundecanoyl PC and Dipalmitoyl PC. LRH-1 (Lee and 
Moore, 2008).It also controls critical enzymes for cholesterol homeostasis and 
bile-acid biosynthesis and expression of aromatase in the breast and ovaries 
(Lee et al., 2008; Santen et al., 2009). 
1.4.4 CARβ and ligands
These have also been explored vigorously for possible ligands and the 
prominent transmitters found include Androstanol and Androstenol.
1.4.5. bγR receptors and benzoate ligands
These receptors, identified as an obligate RXR heterodimeric partner, both 
in vitro and in vivo are mainly found with nervous tissues associated with 
embryonic fluid and show prominent affinity to benzoate derivatives as Ligands 
e.g. Paraaminobenzoic acid (PABA) (Smith et al. 1994a). Bioactivity guided 
HPLC fractionation of embryonic extracts, for stimulation of BXR target 
genes, revealed several components and scale-up purification followed by 





hydroxy benzoic acids as potent, stereo selective activators verified as ligands 
by in vitro (Blumberg et al. 1998a).
1.4.6. PαR Pregnane activated receptors:
These receptors show prominent binding and activation by synthetic steroids, 
steroid antagonists, spironolactones, Cyproterones, PLN and other catatonic 
compounds including Natural sterols.
Exogenous steroids and pharmacologic substances and such catatoxic 
compounds like synthetic glucocorticoid antagonist, pregnenolone-16-
carbonitrile (PCN) may modify the expression of enzymes and induce 
the proliferation of hepatic endoplasmic reticulum and the expression of 
cytochrome P450 genes that would protect against subsequent exposure to 
toxic xenobiotic substances, endogenous steroids, hormones and drugs (Selye 
1971) giving nonspecific protection or immunity against numerous drugs and 
xenobiotic compounds, by increased catabolism by acting through SXR 5 
receptor systems (Burger et al. 1992; Gonzalez et al. 1986). The important 
transmitters include various in use drugs, Rifampicin, Nifedipine, Estrogen, 
Tamoxifen, Phytoestrogens etc. Many of the most potent catatoxic compounds 
(e.g., cyproterone acetate, PCN, spironolactone) are steroid receptor 
antagonists, others (e.g., dexamethasone) are receptor agonists (Burger et al. 
1992). 
1.4.7. pDARγ and ligands
Many compounds have been screened and the potent transmitters or ligands 
discovered include oxidized low density lipoproteins OX-LDL and 9 and 13 
Hydroxy Octadecadienoic acid. 
1.5 Concluding Remarks
The drug discovery process has benefitted well from the two way process 
of identification of ligands such as biologically active peptides and their 
counterpart receptors, thus giving a proper picture of various ligand–receptor 
systems, which are an integral part involved in the therapeutical action of 
various drugs used in various disease conditions. This drug discovery process 
is now utilizing three basic tools for discovery: genomics, high-throughput 
receptor and ligand interaction assays, and large library of biologically active 
molecules. Genomics has provided considerable opportunities in receptor 
identification and discovery and more of such orphan receptors can be 
confirmed after identification of their natural ligands. The future opportunities 
involve identification of more such new receptor–ligand system of therapeutic 
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